Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04603001 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 26, 2020
Last Update Posted : May 31, 2023
|
Sponsor:
Eli Lilly and Company
Collaborator:
Loxo Oncology, Inc.
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS) Chronic Myelomonocytic Leukemia (CMML) Myeloproliferative Neoplasms (MPNs) | Drug: LY3410738 Drug: Venetoclax Drug: Azacitidine | Phase 1 |
This study includes 2 parts: dose escalation and dose expansion. The dose escalation will enroll eligible patients with select IDH-mutant advanced hematologic malignancies. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of LY3410738 is established, the dose expansion will begin and enroll into 5 cohorts to further evaluate safety and clinical activity
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 260 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations |
| Actual Study Start Date : | December 1, 2020 |
| Estimated Primary Completion Date : | August 2023 |
| Estimated Study Completion Date : | May 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Familial acute myeloid leukemia with mutated CEBPA
Cytogenetically normal acute myeloid leukemia
Core binding factor acute myeloid leukemia
Genetic and Rare Diseases Information Center resources:
Myeloid Leukemia
Acute Myeloid Leukemia
Acute Non Lymphoblastic Leukemia
Chronic Graft Versus Host Disease
Myelodysplastic Syndromes
Chronic Myeloproliferative Disorders
Chronic Myelomonocytic Leukemia
Juvenile Myelomonocytic Leukemia
Acute Graft Versus Host Disease
Myelodysplastic/myeloproliferative Disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dose Escalation Arm A (Monotherapy)
Patients not requiring a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
|
Drug: LY3410738
Oral LY3410738 |
|
Experimental: Dose Escalation Arm B (Monotherapy)
Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
|
Drug: LY3410738
Oral LY3410738 |
|
Experimental: Dose Escalation Arm C (LY3410738, Venetoclax, and Azacitidine)
Patients with no prior venetoclax therapy and not requiring a strong CYP3A4 inhibitor for active treatment within 7 days of starting LY3410738.
|
Drug: LY3410738
Oral LY3410738 Drug: Venetoclax Oral venetoclax Drug: Azacitidine Subcutaneous or intravenous azacitidine |
|
Experimental: Cohort 1
Patients with relapsed/refractory (R/R) AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
|
Drug: LY3410738
Oral LY3410738 |
|
Experimental: Cohort 2
Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
|
Drug: LY3410738
Oral LY3410738 |
|
Experimental: Cohort 3
Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation.
|
Drug: LY3410738
Oral LY3410738 |
|
Experimental: Cohort 4
Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
|
Drug: LY3410738
Oral LY3410738 |
|
Experimental: Cohort 5
Patients with newly diagnosed AML, R/R AML, or other advanced hematologic malignancy harboring IDH1 and/or IDH2 mutations with no prior venetoclax therapy. Strong CYP3A4 inhibitor allowed but not required.
|
Drug: LY3410738
Oral LY3410738 Drug: Venetoclax Oral venetoclax Drug: Azacitidine Subcutaneous or intravenous azacitidine |
Primary Outcome Measures :
- To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) [ Time Frame: Up to 30 months ]For Dose Escalation
- To assess the activity of LY3410738 as measured by the overall response rate (ORR) per the Investigator assessment [ Time Frame: Up to 30 months ]For Dose Expansion
Secondary Outcome Measures :
- To determine the safety profile and tolerability of LY3410738 including acute and chronic toxicities by collecting and evaluating adverse events and treatment emergent adverse events [ Time Frame: Up to 30 months ]For Dose Escalation
- To characterize the pharmacokinetics (PK) properties of LY3410738 by collecting and evaluating serum at protocol specified time points [ Time Frame: Up to 30 months ]For Dose Escalation
- To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma [ Time Frame: Up to 30 months ]For Dose Escalation
- To assess the activity of LY3410738 as measured by the overall response rate (ORR) per Investigator assessment [ Time Frame: Up to 30 months ]For Dose Escalation
- To assess the activity of LY3410738 as measured by Best Overall Response (BOR) per Investigator assessment [ Time Frame: Up to 30 months ]For Dose Expansion
- To assess the activity of LY3410738 by Complete Remission (CR) Rate (CRR) plus partial hematologic recovery (AML patients) [ Time Frame: Up to 30 months ]For Dose Expansion
- To assess the activity of LY3410738 by Duration of Response [ Time Frame: Up to 30 months ]For Dose Expansion
- To assess the activity of LY3410738 by Hematologic improvement in patients with MDS [ Time Frame: Up to 30 months ]For Dose Expansion
- To determine the safety profile and tolerability of LY3410738 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events [ Time Frame: Up to 30 months ]For Dose Expansion
- To characterize the pharmacokinetics (PK) properties of LY3410738 by collecting and evaluating serum at protocol specified time points [ Time Frame: Up to 30 months ]For Dose Expansion
- To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma. [ Time Frame: Up to 30 months ]For Dose Expansion
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Advanced IDH mutant hematologic malignancy including:
-- For Dose Escalation Arm C and Dose Expansion Cohort 5:
- Patients with newly diagnosed AML who are 75 years or older or have comorbidities that preclude the use of intensive chemotherapy
- Patients with R/R AML (US only)
- Patients must have received prior therapy
- Blasts at least 5% in bone marrow.
- Patients must have a qualifying IDH1 R132, IDH2 R140 or IDH2 R172 mutation
- Eastern Cooperative Oncology Group (ECOG) 0 to 2
- Adequate organ function
- Ability to swallow capsules or tablets
- Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation
- Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment.
Exclusion Criteria:
- Investigational agent or anticancer therapy within 2 weeks or 5 half-lives, whichever is shorter; or investigational monoclonal antibody within 4 weeks prior to planned start of LY3410738
-
For Dose Escalation Arm C and Dose Expansion Cohort 5:
- Prior venetoclax treatment is not allowed.
- Patients are allowed to receive up to 1 cycle of single agent azacitidine or azacitidine plus venetoclax while waiting for results of locally obtained molecular profiling, including IDH1/IDH2 mutational status, prior to starting on study.
- Major surgery within 4 weeks prior to planned start of LY3410738.
- Active, uncontrolled clinically significant systemic bacterial, viral, fungal or parasitic infection or an unexplained fever > 38.5ºC during Screening or on the first day of study drug administration.
- Another concurrent malignancy requiring active therapy.
- Active central nervous system involvement
- Any unresolved toxicities from prior therapy greater than CTCAE v5.0 Grade 2 at the time of starting study treatment except for alopecia.
- History of hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy within 60 days of the first dose of LY3410738.
- Clinically significant cardiovascular disease
- Active hepatitis B virus (HBV)
- Active hepatitis C virus (HCV)
- Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug
- Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and/or P- glycoprotein (P-gp) inhibitor, with the exception of patients being treated with allowed antifungal inhibitors of CYP3A4
- Treatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738
- Any serious underlying medical or psychiatric condition (e.g. alcohol or drug abuse), dementia or altered mental status or any issue that would impair the ability of the patient to understand informed consent or that in the opinion of the Investigator would contraindicate the patient's participation in the study or confound the results of the study
- Known human immunodeficiency virus (HIV), excluded due to potential drug-drug interactions between antiretroviral medications and LY3410738
- Pregnancy, lactation or plan to breastfeeding during the study or within 90 days of the last dose of study intervention
- Known hypersensitivity to any of the components of LY3410738 or its formulation
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04603001
Locations
Show 37 study locations
Sponsors and Collaborators
Eli Lilly and Company
Loxo Oncology, Inc.
Investigators
| Study Director: | Yin Zhang, MD | Loxo Oncology |
Additional Information:
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT04603001 |
| Other Study ID Numbers: |
LOXO-IDH-20001 2020-002830-33 ( EudraCT Number ) I9Y-OX-JDHB ( Other Identifier: Eli Lilly and Company ) |
| First Posted: | October 26, 2020 Key Record Dates |
| Last Update Posted: | May 31, 2023 |
| Last Verified: | May 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Eli Lilly and Company:
|
Loxo LY3410738 isocitrate dehydrogenase IDH IDH1 IDH2 R132 R140 R172 2-hydroxyglutarate 2-HG Advanced Hematologic Malignancies Blasts Acute Myeloid Leukemia AML |
Relapsed/refractory AML R/R AML Myelodysplastic Syndrome MDS Chronic Myelomonocytic Leukemia CMML Myeloproliferative Neoplasms MPN Advanced Hematologic Cancers Ivosidenib AG-120 Vorasidenib AG-881 Olutasidenib FT-2102 |
Additional relevant MeSH terms:
|
Leukemia Neoplasms Leukemia, Myeloid Leukemia, Myeloid, Acute Preleukemia Hematologic Neoplasms Leukemia, Myelomonocytic, Chronic Leukemia, Myelomonocytic, Juvenile Myelodysplastic Syndromes Myeloproliferative Disorders Pathologic Processes Neoplasms by Histologic Type Bone Marrow Diseases |
Hematologic Diseases Precancerous Conditions Neoplasms by Site Myelodysplastic-Myeloproliferative Diseases Chronic Disease Disease Attributes Azacitidine Venetoclax Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |